首页> 美国政府科技报告 >Immunological Response to Diphtheria/Tetanus Vaccine in Schistosomiasis MansoniPatients
【24h】

Immunological Response to Diphtheria/Tetanus Vaccine in Schistosomiasis MansoniPatients

机译:血吸虫病mansoni患者白喉/破伤风疫苗的免疫应答

获取原文

摘要

The cellular and humoral immune responses of patients with S. mansoni infectionwere evaluated before and one month after each of two intramuscular doses of diphtheria/tetanus toxoid vaccine. Patients were divided into 'responder' and 'non-responder' groups based on anti-tetanus toxoid (anti-TT) IgG levels after vaccination. The specific anti-TT IgGl response of the responder group was predominantly in the IgG, subclass. The lymphoproliferative response to PHA was also significantly higher in the responder group; this elevation was detectable before and after each vaccination. The responses to PWM and SPL were comparable in the two groups before vaccination, although the responder group had a higher response to SPL after vaccination. IgG antibodies for schistosome adult worm and egg antigens were significantly lower in the responder group prior to vaccination but not thereafter. Anti-diphtheria IgG antibodies were comparable in the two groups after vaccination at all times. Clinically, the non-responder patients had a higher incidence of splenomegaly (84.6 % vs 44.8 %) and were significantly older that the responder patients (mean 34.1 yrs vs 18.7 yrs). The cause for the reduced anti-tetanus IgG response in schistosomiasis patients is believed to be multifactorial. T cell or antigen presenting cell dysfunction, high levels of IgG antibodies specific for schistosome antigens, splenomegaly and age are factors that might lead to reduced anti-T7 IgG response.... Diphtheria/Tetanus toxoid vaccine, S. Mansoni, Immunological responses, Patients, Egypt.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号